Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases.
Share Price & News
How has Moderna's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MRNA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: MRNA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: MRNA exceeded the US Biotechs industry which returned 25.7% over the past year.
Return vs Market: MRNA exceeded the US Market which returned 33.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Moderna's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StRepeated Vaccination and S&P500 Inclusion Support the Generous Moderna (NASDAQ: MRNA) Valuation
9 months ago | Simply Wall StWhat You Need To Know About Moderna (NasdaqGS:MRNA) Stock
9 months ago | Simply Wall StIndustry Analysts Just Upgraded Their Moderna, Inc. (NASDAQ:MRNA) Revenue Forecasts By 10%
Moderna Fundamentals Summary
|MRNA fundamental statistics|
Is MRNA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MRNA income statement (TTM)|
|Cost of Revenue||US$2.88b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||8.77|
|Net Profit Margin||49.79%|
How did MRNA perform over the long term?See historical performance and comparison
Is Moderna undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MRNA ($430.05) is trading above our estimate of fair value ($63.04)
Significantly Below Fair Value: MRNA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MRNA is poor value based on its PE Ratio (49.7x) compared to the US Biotechs industry average (25x).
PE vs Market: MRNA is poor value based on its PE Ratio (49.7x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: MRNA's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: MRNA is overvalued based on its PB Ratio (25.9x) compared to the US Biotechs industry average (3.2x).
How is Moderna forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MRNA's earnings are forecast to decline over the next 3 years (-48.5% per year).
Earnings vs Market: MRNA's earnings are forecast to decline over the next 3 years (-48.5% per year).
High Growth Earnings: MRNA's earnings are forecast to decline over the next 3 years.
Revenue vs Market: MRNA's revenue is expected to decline over the next 3 years (-28.7% per year).
High Growth Revenue: MRNA's revenue is forecast to decline over the next 3 years (-28.7% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MRNA's Return on Equity is forecast to be low in 3 years time (2.2%).
How has Moderna performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MRNA has high quality earnings.
Growing Profit Margin: MRNA became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: MRNA has become profitable over the past 5 years, growing earnings by 46% per year.
Accelerating Growth: MRNA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MRNA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: MRNA's Return on Equity (52.1%) is considered outstanding.
How is Moderna's financial position?
Financial Position Analysis
Short Term Liabilities: MRNA's short term assets ($11.0B) exceed its short term liabilities ($8.8B).
Long Term Liabilities: MRNA's short term assets ($11.0B) exceed its long term liabilities ($609.0M).
Debt to Equity History and Analysis
Debt Level: MRNA is debt free.
Reducing Debt: MRNA had no debt 5 years ago.
Debt Coverage: MRNA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: MRNA has no debt, therefore coverage of interest payments is not a concern.
What is Moderna current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MRNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MRNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MRNA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MRNA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MRNA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stephane Bancel (48 yo)
Mr. Stephane Bancel serves as Board Director of Indigo Agriculture Inc since 2020. Mr Bancel serves as Interim President of Valera LLC. Mr. Bancel serves as a Special Partner at Flagship Pioneering since F...
CEO Compensation Analysis
Compensation vs Market: Stephane's total compensation ($USD12.86M) is about average for companies of similar size in the US market ($USD11.36M).
Compensation vs Earnings: Stephane's compensation has been consistent with company performance over the past year.
Experienced Management: MRNA's management team is considered experienced (3.3 years average tenure).
Experienced Board: MRNA's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.
Moderna, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Moderna, Inc.
- Ticker: MRNA
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$173.588b
- Shares outstanding: 403.65m
- Website: https://www.modernatx.com
Number of Employees
- Moderna, Inc.
- 200 Technology Square
- United States
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 22:12|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.